Online Education

How Does Blood Clot?

The purpose of this activity is to enable the learner to improve understanding of and increase interest in the basic concepts involved in the complex coagulation process to ultimately improve patient care.

• Examine the coagulation process from the point of injury to clot resolution.
• Evaluate the platelet reaction step of normal hemostasis.
• Differentiate among the three coagulation pathways, including the various clotting factors that participate in hemostasis.

Nurses and other healthcare staff employed within or affiliated with the U.S. Hemophilia Treatment Center (HTC) network.

An animated module illustrating the coagulation cascade.

• Roshni Kulkarni, MD
• Usha M. Reddy, MD
• Bruce L. Evatt, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

VWD and Women's Issues

This program aims to illustrate that women with bleeding disorders are disproportionately affected not only by menorrhagia, but by other obstetrical and gynecological conditions that manifest with bleeding.

Healthcare professionals seeking increased knowledge about von Willebrand disease (VWD) in women.

This evidence-based module, "VWD and Women's Issues" provides information about obstetrical and gynecological manifestations of a bleeding disorder. The module uses recent data and research to support the relationship between symptoms of bleeding and diagnosis of VWD. Finally, this module discusses considerations that must be made for women with VWD before, during, and after delivery.

• Andra James, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

Hemophilia in Pictures

The purpose of Hemophilia in Pictures is to provide basic knowledge about hemophilia through pictures and easy-to-understand information.

Hemophilia in Pictures has many goals. Please refer to the HIP Educators Guide to learn more about the educational goals for Educators as well as People with Hemophilia.

Hemophilia in Pictures is for hemophilia educators and people with hemophilia alike. The information is basic and is provided through pictures and easy-to-understand language, so it is accessible to anyone.

This online learning module covers a range of topics, including an introduction to hemophilia, assessing and managing bleeds, treatment of bleeds, staying healthy and preventing bleeds, and venipuncture and home therapy.

• Lara Oyesiku, Chair of the HIP Working Group and Nurse's Committee, England
• Martin Bedford, Educational Advisor, England
• Annie Gillham, Nurse Advisor, South Africa
• Dr. Peter Jones, Medical Advisor, England
• Kathy Mulder, Physiotherapy Advisor, Canada
• David Page, Educational Advisor, Canada
• Laurie Blackstock, WFH Education Officer

2005

Upon launching the presentation, there are three handouts available for you to print or save for future reference: Educator Guide, Educator Glossary, and On Screen Notes.
To access the handouts, click on the paperclip icon located in the lower right portion of the presentation box.

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CC040 - Bleeding Disorders Interactive Primer: Bleeding Disorders in Women

Bleeding Disorders in Women is an interactive learning activity that describes the genetics of hemophilia and von Willebrand disease (VWD). Determination of carrier status, appropriate selection of treatment products, and neonatal concerns/prenatal diagnosis of infants potentially affected by hemophilia is also examined. The learner will be presented with Reading Room material that may be printed or saved for future reference. Three case studies are presented with patient chart information and interactive question-and-answer slides to allow the learner the opportunity to apply what has been learned.

TThe purpose of this module is to review the unique considerations of bleeding disorders in women, including genetics of hemophilia and von Willebrand disease, accurate determination of carrier status, appropriate selection of treatment products, and neonatal concerns/prenatal diagnosis of infants potentially affected by hemophilia.

• Analyze the genetics of hemophilia and von Willebrand disease and the importance of genetic testing
• Investigate bleeding problems in carriers of hemophilia
• Relate methods to accurately determine the carrier state of a patient
• Recommend appropriate treatment products for carriers of hemophilia as well as for infrequently or previously unexposed patients
• Detect the various neonatal considerations in hemophilia care
• Assess prenatal diagnosis of infants potentially affected by hemophilia

This learning activity is intended for physicians and nursing professionals at federally funded hemophilia treatment centers (HTCs) and health care providers in other health care settings, such as emergency and primary care, and obstetrics and gynecology.

• Meera Chitlur, MD
• Madhvi V. Rajpurkar, MD
• Natalie A. Duncan, MPH (Editor)
• Susan C. Zappa, RN, CPN (Peer reviewer/Editor)

April 1, 2016

5:00 PM Eastern, March 30, 2018

In accordance with the ACCME Standards for Commercial Support of CME, The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (Indiana Hemophilia and Thrombosis Center (IHTC)) have implemented mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a person with a financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) have identified and resolved any and all conflicts of interest prior to the release of this activity.

The speakers and planning committee members listed below have stated they have no significant or substantial relationship with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity:

• Catherine Bevil, EdD, RN
• Lois Colburn
• Natalie A. Duncan, MPH
• Diane Frost, MA, CPP
• Heidi Keeler, PhD, RN

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information the planned and/or present is done so fairly and without bias:

• Anu Hosangadi, MS states that she owns stock in Merck, Bristol Myers Squibb, and Johnson & Johnson.
• Jennifer Maahs, MSN, PNP states the she is on the Advisory Board for Baxalta, Biogen, and Novo Nordisk. Ms. Maahs is on the Speakers Bureau for Baxalta and Biogen.
• Margaret Ragni, MD, MPH states that she is on the Advisory Committee/Board for Alnylam and Medscape/Web MD/Biogen. Dr. Ragni has been a chair, speaker at symposium for Baxalta. Dr. Ragni has received research funding from Alnylam, Baxter, Bayer, and SPARK. She has conducted research studies for BSL Behring, Dimension, and Genentech Roches. Dr. Ragni is a consultant for Biomarin, Shire, and Tacere Benitec. She has prepared education materials and speaks for Medscape/WebMD/Biogen and is a DSMB member for Tacere Benitec.
• Amy D. Shapiro, MD states that she is on the Global Steering Committee for Baxalta. Dr. Shapiro is a consultant for Baxalta, Novo Nordisk, Biogen Idec, ProMetic Life Sciences, and Kedrion Biopharma. She is on the Advisory Board for Baxalta, Novo Nordisk, and Biogen IDEC. Dr. Shapiro is on the Data Safety Monitoring Board for Baxalta and is a member of the Novo Nordisk Hemophilia Foundation, and the International Network on Pediatric Hemophilia for Bayer Healthcare Pharmaceuticals. Dr. Shapiro has clinical research protocols with the following: Bayer Healthcare, Biogen Idec, Kedrion Biopharma, Octopharma, PTC Therapeutics, Baxalta, CSL Behring, Novartis Pharmaceuticals, and ProMetic Life Sciences. Dr. Shapiro is Medical Director for the American Thrombosis and Hemostasis Network (ATHN) National Hemophilia Program Coordinating Center and a member of the Medical and Scientific Advisory Council for the National Hemophilia Foundation. Dr. Shapiro notes that she does not accept honoraria personally, and all honoraria or income (grant research funding and consultant fees) generated from the activities above are paid to the Indiana Hemophilia & Thrombosis Center. She has no financial interest in any of the companies.
• Susan C. Zappa, RN, CPN states that she is a consultant and on the Speakers Bureaus for Pfizer, Bayer, and Baxalta. Ms. Zappa is a consultant for Emergent, Novo Nordisk, Grifols, and Octopharma.

The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) requires CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 60 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Review the activity objectives and CME/CE information.
• Review the case and answer the interactive questions.
• Review the Reading Room material, the patient charts, and laboratory data.
• Complete the evaluation, including the attestation of hours attended.
• Complete the post-test with a score of 80% or better.
• Nurses and "other" disciplines: upon successful completion of the post-test your certificate of completion will be available to save or print.
• MDs and PAs: your certificate of completion will be emailed to you by the Center for Continuing Education. For questions, please call Brenda Ram at 402-559-9250 or email bram@unmc.edu.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and Indiana Hemophilia & Thrombosis Center, Inc. (Partners in Bleeding Disorders Education).

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

This activity is provided for 1.0 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

This program is not supported by any commercial or financial interest.

Partners in Bleeding Disorders Education would like to acknowledge the following original contributors of previous versions of the Bleeding Disorders Interactive Primer (Hemophilia Primer) project:

• Alice Ma, MD
• Andra James, MD, MPH
• Bruce Ewenstein, MD, PhD
• Christine Kempton, MD, MSc
• Deborah Brown, MD
• Georges Rivard, MD
• Guy Young, MD
• Jorge Di Paola, MD
• Margaret Ragni, MD, MPH
• Marilyn Manco-Johnson, MD
• Peter Kouides, MD
• Stephanie Seremetis, MD
• Suchitra Acharya, MD
• Sweta Gupta, MBBS, MD, MS
• Thomas Abshire, MD
• Victor Blanchette, MD, FRCP
• W. Keith Hoots, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

17CE042 - Transition Improvement Process

The purpose of this activity is to enable the health care provider to identify the important elements of a transition program and to provide the healthcare provider with detailed instructions for transitioning patients ages 12 through 22.

• Use a systematic approach to youth to young adult transition in blood disorders health care
• Evaluate the transition process at your Hemophilia Treatment Center (HTC)
• Identify best-practice transition resources, such as those found on GotTransition.org
• Apply transition processes at your HTC

Nurses and other health care providers serving the bleeding disorders community

Transition Improvement Process will describe the core elements of a transition program, provide detailed instructions on implementing such a program, and offers tools to measure progress and track improvement over time. Video demonstration is provided in addition to numerous PDF resources that the healthcare provider can download for modification and use in their current practice.

• Natalie Duncan, MPH
• Deborah Brown, MD
• Ann Forsberg, MA, MPH
• Rebecca Malouin, PhD, MPH, MS
• Brittany Molter, MSN, AGPCNP-BC
• Kathaleen Schnur, LSW
• Penni Smith, BSN, RN

February 13, 2017

5:00 PM, Eastern, February 13, 2018

The estimated time to complete this activity is 60 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Read the Program Announcement Form
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

This activity is provided for 1.0 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CC039 - Bleeding Disorders Interactive Primer: von Willebrand Disease (Module 1)

Von Willebrand Disease (Module 1) is an interactive learning activity that describes the genetics and subtyping of von Willebrand disease (VWD) and their importance in diagnosing and managing VWD. Additional material covered includes thrombocytopenia and VWD, obstetric and gynecologic issues in women with bleeding disorders, suggested questions for screening persons for a bleeding disorders, and appropriate treatment options for VWD, including replacement therapy and use of topical and other adjunctive agents. The learner will be presented with Reading Room material that may be printed or saved for future reference. Two case studies are presented with patient chart information and interactive question-and-answer slides to allow the learner the opportunity to apply what has been learned.

The purpose of this activity is to describe the genetics and subtyping of von Willebrand disease (VWD) and their importance in diagnosing and managing VWD. The activity reviews appropriate treatment options, including replacement therapy and use of topical and other adjunctive agents.

• Use suggested questions for screening persons for a bleeding disorder
• Differentiate among the subtypes of von Willebrand disease (VWD)
• Explain the genetics of VWD
• Examine the clinical management of women with bleeding disorders
• Relate the possible causes of thrombocytopenia in people with VWD
• Evaluate the appropriate replacement products for VWD
• Assess the value of fibrin glue and other modalities to treat epistaxis
• Identify one outcome associated with prophylactic treatment of VWD

This learning activity is intended for physicians and nursing professionals at federally funded hemophilia treatment centers (HTCs) and health care providers in other health care settings, such as emergency and primary care, and obstetrics and gynecology.

• Suchitra S. Acharya, MD
• Peter A. Kouides, MD
• Natalie A. Duncan, MPH (Editor)
• Susan C. Zappa, RN, CPN (Peer reviewer/Editor)

April 1, 2016

5:00 PM Eastern, March 30, 2018

In accordance with the ACCME Standards for Commercial Support of CME, The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (Indiana Hemophilia and Thrombosis Center (IHTC)) have implemented mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a person with a financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) have identified and resolved any and all conflicts of interest prior to the release of this activity.

The speakers and planning committee members listed below have stated they have no significant or substantial relationship with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity:

• Catherine Bevil, EdD, RN
• Lois Colburn
• Natalie A. Duncan, MPH
• Diane Frost, MA, CPP
• Heidi Keeler, PhD, RN

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information the planned and/or present is done so fairly and without bias:

• Suchitra S. Acharya, MD states that she is on the Advisory Committee/Board for Novo Nordisk and Bayer. Dr. Acharya received industry funded research/investigator from Bayer.
• Anu Hosangadi, MS states that she owns stock in Merck, Bristol Myers Squibb, and Johnson & Johnson.
• Peter Kouides, MD states that he is on the Advisory Committee/Board for CSL Behring. Dr. Kouides is a consultant for Baxalta, Octapharma, and Grifols. Dr. Kouides is an unpaid member of study for Grifols.
• Jennifer Maahs, MSN, PNP states the she is on the Advisory Board for Baxalta, Biogen, and Novo Nordisk. Ms. Maahs is on the Speakers Bureau for Baxalta and Biogen.
• Amy D. Shapiro, MD states that she is on the Global Steering Committee for Baxalta. Dr. Shapiro is a consultant for Baxalta, Novo Nordisk, Biogen Idec, ProMetic Life Sciences, and Kedrion Biopharma. She is on the Advisory Board for Baxalta, Novo Nordisk, and Biogen IDEC. Dr. Shapiro is on the Data Safety Monitoring Board for Baxalta and is a member of the Novo Nordisk Hemophilia Foundation, and the International Network on Pediatric Hemophilia for Bayer Healthcare Pharmaceuticals. Dr. Shapiro has clinical research protocols with the following: Bayer Healthcare, Biogen Idec, Kedrion Biopharma, Octopharma, PTC Therapeutics, Baxalta, CSL Behring, Novartis Pharmaceuticals, and ProMetic Life Sciences. Dr. Shapiro is Medical Director for the American Thrombosis and Hemostasis Network (ATHN) National Hemophilia Program Coordinating Center and a member of the Medical and Scientific Advisory Council for the National Hemophilia Foundation. Dr. Shapiro notes that she does not accept honoraria personally, and all honoraria or income (grant research funding and consultant fees) generated from the activities above are paid to the Indiana Hemophilia & Thrombosis Center. She has no financial interest in any of the companies.
• Susan C. Zappa, RN, CPN states that she is a consultant and on the Speakers Bureaus for Pfizer, Bayer, and Baxalta. Ms. Zappa is a consultant for Emergent, Novo Nordisk, Grifols, and Octopharma.

The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) requires CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

• Use of Koate-DVI in VWD discussed in case studies

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 45 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Review the activity objectives and CME/CE information.
• Review the case and answer the interactive questions.
• Review the Reading Room material, the patient charts, and laboratory data.
• Complete the evaluation, including the attestation of hours attended.
• Complete the post-test with a score of 75% or better.
• Nurses and "other" disciplines: upon successful completion of the post-test your certificate of completion will be available to save or print.
• MDs and PAs: your certificate of completion will be emailed to you by the Center for Continuing Education. For questions, please call Brenda Ram at 402-559-9250 or email bram@unmc.edu.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and Indiana Hemophilia & Thrombosis Center, Inc. (Partners in Bleeding Disorders Education).

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

This activity is provided for 0.75 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

This program is not supported by any commercial or financial interest.

Partners in Bleeding Disorders Education would like to acknowledge the following original contributors of previous versions of the Bleeding Disorders Interactive Primer (Hemophilia Primer) project:

• Alice Ma, MD
• Andra James, MD, MPH
• Bruce Ewenstein, MD, PhD
• Christine Kempton, MD, MSc
• Deborah Brown, MD
• Georges Rivard, MD
• Guy Young, MD
• Jorge Di Paola, MD
• Margaret Ragni, MD, MPH
• Marilyn Manco-Johnson, MD
• Peter Kouides, MD
• Stephanie Seremetis, MD
• Suchitra Acharya, MD
• Sweta Gupta, MBBS, MD, MS
• Thomas Abshire, MD
• Victor Blanchette, MD, FRCP
• W. Keith Hoots, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CC041 - Bleeding Disorders Interactive Primer: von Willebrand Disease (Module 2)

on Willebrand Disease (Module 2) is an interactive learning activity that describes subtypes and inheritance of von Willebrand disease (VWD) and the clinical manifestations of VWD type 3. The activity covers the challenges in diagnosing hemostatic abnormalities, such as VWD in neonates and recognizing bleeding disorders in women with heavy menstrual bleeding (HMB). Finally, the activity reviews hemostatic interventions for management of VWD and HMB in women with bleeding disorders.
The learner will be presented with Reading Room material that may be printed or saved for future reference. A case study is presented with patient chart information and interactive question-and-answer slides to allow the learner the opportunity to apply what has been learned.

The purpose of this learning activity is to describe subtypes and inheritance of von Willebrand disease (VWD) and the clinical manifestations of VWD type 3. The activity covers the challenges in diagnosing hemostatic abnormalities such as VWD in neonates and recognizing bleeding disorders in women with heavy menstrual bleeding (HMB). Finally, the activity reviews hemostatic interventions for management of VWD and HMB in women with bleeding disorders.

• Differentiate among the subtypes of von Willebrand disease (VWD)
• Describe VWD inheritance patterns and associated symptoms
• Identify the clinical manifestations of type 3 VWD
• Examine the challenges in diagnosing hemostatic abnormalities in neonates
• Discuss recognition of bleeding disorders in women with heavy menstrual bleeding (HMB)
• Evaluate hemostatic interventions for the management of VWD
• Describe the management of VWD-related HMB

This learning activity is intended for physicians and nursing professionals at federally funded hemophilia treatment centers (HTCs) and health care providers in other health care settings, such as emergency and primary care, and obstetrics and gynecology.

• Meera Chitlur, MD
• Madhvi V. Rajpurkar, MD
• Natalie A. Duncan, MPH (Editor)
• Susan C. Zappa, RN, CPN (Peer reviewer/Editor)

April 1, 2016

5:00 PM Eastern, March 30, 2018

In accordance with the ACCME Standards for Commercial Support of CME, The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (Indiana Hemophilia and Thrombosis Center (IHTC)) have implemented mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a person with a financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) have identified and resolved any and all conflicts of interest prior to the release of this activity.

The speakers and planning committee members listed below have stated they have no significant or substantial relationship with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity:

• Catherine Bevil, EdD, RN
• Lois Colburn
• Natalie A. Duncan, MPH
• Diane Frost, MA, CPP
• Heidi Keeler, PhD, RN

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information the planned and/or present is done so fairly and without bias:

• Meera Chitlur, MD states that she is a consultant for Novo Nordisk. Dr. Chitlur is on Advisory Boards/Committees for Baxalta, Bayer, Biogen Idec.
• Anu Hosangadi, MS states that she owns stock in Merck, Bristol Myers Squibb, and Johnson & Johnson.
• Madhvi V. Rajpurkar, MD states that she is on Advisory Boards/Committees for Baxalta, Novo Nordisk, Pfizer, and Bayer.
• Jennifer Maahs, MSN, PNP states the she is on the Advisory Board for Baxalta, Biogen, and Novo Nordisk. Ms. Maahs is on the Speakers Bureau for Baxalta and Biogen.
• Amy D. Shapiro, MD states that she is on the Global Steering Committee for Baxalta. Dr. Shapiro is a consultant for Baxalta, Novo Nordisk, Biogen Idec, ProMetic Life Sciences, and Kedrion Biopharma. She is on the Advisory Board for Baxalta, Novo Nordisk, and Biogen IDEC. Dr. Shapiro is on the Data Safety Monitoring Board for Baxalta and is a member of the Novo Nordisk Hemophilia Foundation, and the International Network on Pediatric Hemophilia for Bayer Healthcare Pharmaceuticals. Dr. Shapiro has clinical research protocols with the following: Bayer Healthcare, Biogen Idec, Kedrion Biopharma, Octopharma, PTC Therapeutics, Baxalta, CSL Behring, Novartis Pharmaceuticals, and ProMetic Life Sciences. Dr. Shapiro is Medical Director for the American Thrombosis and Hemostasis Network (ATHN) National Hemophilia Program Coordinating Center and a member of the Medical and Scientific Advisory Council for the National Hemophilia Foundation. Dr. Shapiro notes that she does not accept honoraria personally, and all honoraria or income (grant research funding and consultant fees) generated from the activities above are paid to the Indiana Hemophilia & Thrombosis Center. She has no financial interest in any of the companies.
• Susan C. Zappa, RN, CPN states that she is a consultant and on the Speakers Bureaus for Pfizer, Bayer, and Baxalta. Ms. Zappa is a consultant for Emergent, Novo Nordisk, Grifols, and Octopharma.

The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) requires CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 45 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Review the activity objectives and CME/CE information.
• Review the case and answer the interactive questions.
• Review the Reading Room material, the patient charts, and laboratory data.
• Complete the evaluation, including the attestation of hours attended.
• Complete the post-test with a score of 75% or better.
• Nurses and "other" disciplines: upon successful completion of the post-test your certificate of completion will be available to save or print.
• MDs and PAs: your certificate of completion will be emailed to you by the Center for Continuing Education.For questions, please call Brenda Ram at 402-559-9250 or email bram@unmc.edu.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and Indiana Hemophilia & Thrombosis Center, Inc. (Partners in Bleeding Disorders Education).

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

This activity is provided for 0.75 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

This program is not supported by any commercial or financial interest.

Partners in Bleeding Disorders Education would like to acknowledge the following original contributors of previous versions of the Bleeding Disorders Interactive Primer (Hemophilia Primer) project:

• Alice Ma, MD
• Andra James, MD, MPH
• Bruce Ewenstein, MD, PhD
• Christine Kempton, MD, MSc
• Deborah Brown, MD
• Georges Rivard, MD
• Guy Young, MD
• Jorge Di Paola, MD
• Margaret Ragni, MD, MPH
• Marilyn Manco-Johnson, MD
• Peter Kouides, MD
• Stephanie Seremetis, MD
• Suchitra Acharya, MD
• Sweta Gupta, MBBS, MD, MS
• Thomas Abshire, MD
• Victor Blanchette, MD, FRCP
• W. Keith Hoots, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CC038 - Bleeding Disorders Interactive Primer: Sports Injuries in Mild Hemophilia

Sports Injuries in Mild Hemophilia is an interactive learning activity that explains the treatment of mild hemophilia, including desmopressin and its potential limitations in patients with mild hemophilia, how RICE therapy can be used in bleeding episodes, and why physical therapy is needed for acute musculoskeletal bleeding episodes. It specifically covers the acute presentation, medical management, and complications of iliopsoas bleeds. The activity also includes guidelines to distinguish mild hemophilia from Type 2N von Willebrand Disease and a list of appropriate sports activities for patients with bleeding disorders. The learner will be presented with Reading Room material that may be printed or saved for future reference. Two case studies are presented with patient chart information and interactive question-and-answer slides to allow the learner the opportunity to apply what has been learned.

The purpose of this activity is to enable the learner to relate to the diagnostics and treatments of sports-related injuries and complications for patients with mild hemophilia.

• Describe the complications of mild hemophilia
• Distinguish mild hemophilia from type 2N von Willebrand disease
• Evaluate the use of desmopressin in patients with mild hemophilia, including its limitations
• Explain how Rest, Ice, Compression, and Elevation (RICE) can be utilized in musculoskeletal bleeding episodes
• Assess the use of physical therapy for managing acute episodes of musculoskeletal bleeding
• Recommend appropriate sports activities for patients with bleeding disorders
• Review the acute presentation and complications of iliopsoas bleeds and their medical management

This learning activity is targeted toward nursing professionals and other members of the multidisciplinary staff at federally funded Hemophilia Treatment Centers (HTCs). The activity also aims to educate physicians and nursing professionals in emergency and primary care, as well as joint/orthopedic health and sports medicine settings.

• Sweta Gupta, MD
• Christine Kempton, MD
• Natalie A. Duncan, MPH (Editor)
• Susan C. Zappa, RN, CPN (Peer reviewer/Editor)

April 1, 2016

5:00 PM Eastern, March 30, 2018

In accordance with the ACCME Standards for Commercial Support of CME, The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (Indiana Hemophilia and Thrombosis Center (IHTC)) have implemented mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a person with a financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) have identified and resolved any and all conflicts of interest prior to the release of this activity.

The speakers and planning committee members listed below have stated they have no significant or substantial relationship with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity:

• Catherine Bevil, EdD, RN
• Lois Colburn
• Natalie A. Duncan, MPH
• Diane Frost, MA, CPP
• Heidi Keeler, PhD, RN

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information the planned and/or present is done so fairly and without bias:

• Anu Hosangadi, MS states that she owns stock in Merck, Bristol Myers Squibb, and Johnson & Johnson.
• Christine Kempton, MD, MSc states that she is a consultant for Hoffman La Roche and Baxalta. Dr. Kempton receives research funding from Novo Nordisk.
• Jennifer Maahs, MSN, PNP states the she is on the Advisory Board for Baxalta, Biogen, and Novo Nordisk. Ms. Maahs is on the Speakers Bureau for Baxalta and Biogen.
• Amy D. Shapiro, MD states that she is on the Global Steering Committee for Baxalta. Dr. Shapiro is a consultant for Baxalta, Novo Nordisk, Biogen Idec, ProMetic Life Sciences, and Kedrion Biopharma. She is on the Advisory Board for Baxalta, Novo Nordisk, and Biogen IDEC. Dr. Shapiro is on the Data Safety Monitoring Board for Baxalta and is a member of the Novo Nordisk Hemophilia Foundation, and the International Network on Pediatric Hemophilia for Bayer Healthcare Pharmaceuticals. Dr. Shapiro has clinical research protocols with the following: Bayer Healthcare, Biogen Idec, Kedrion Biopharma, Octopharma, PTC Therapeutics, Baxalta, CSL Behring, Novartis Pharmaceuticals, and ProMetic Life Sciences. Dr. Shapiro is Medical Director for the American Thrombosis and Hemostasis Network (ATHN) National Hemophilia Program Coordinating Center and a member of the Medical and Scientific Advisory Council for the National Hemophilia Foundation. Dr. Shapiro notes that she does not accept honoraria personally, and all honoraria or income (grant research funding and consultant fees) generated from the activities above are paid to the Indiana Hemophilia & Thrombosis Center. She has no financial interest in any of the companies.
• Susan C. Zappa, RN, CPN states that she is a consultant and on the Speakers Bureaus for Pfizer, Bayer, and Baxalta. Ms. Zappa is a consultant for Emergent, Novo Nordisk, Grifols, and Octopharma.

The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) requires CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 45 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Review the activity objectives and CME/CE information.
• Review the case and answer the interactive questions.
• Review the Reading Room material, the patient charts, and laboratory data.
• Complete the evaluation, including the attestation of hours attended.
• Complete the post-test with a score of 75% or better.
• Nurses and "other" disciplines: upon successful completion of the post-test your certificate of completion will be available to save or print.
• MDs and PAs: your certificate of completion will be emailed to you by the Center for Continuing Education. For questions, please call Brenda Ram at 402-559-9250 or email bram@unmc.edu.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center's Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and Indiana Hemophilia & Thrombosis Center, Inc. (Partners in Bleeding Disorders Education).

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

This activity is provided for 0.75 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

This program is not supported by any commercial or financial interest.

Partners in Bleeding Disorders Education would like to acknowledge the following original contributors of previous versions of the Bleeding Disorders Interactive Primer (Hemophilia Primer) project:

• Alice Ma, MD
• Andra James, MD, MPH
• Bruce Ewenstein, MD, PhD
• Christine Kempton, MD, MSc
• Deborah Brown, MD
• Georges Rivard, MD
• Guy Young, MD
• Jorge Di Paola, MD
• Margaret Ragni, MD, MPH
• Marilyn Manco-Johnson, MD
• Peter Kouides, MD
• Stephanie Seremetis, MD
• Suchitra Acharya, MD
• Sweta Gupta, MBBS, MD, MS
• Thomas Abshire, MD
• Victor Blanchette, MD, FRCP
• W. Keith Hoots, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CC045 – Bleeding Disorders Interactive Primer: Emergency Care of Bleeding Disorders

Emergency Care of Bleeding Disorders is an interactive learning activity that explores issues relating to the emergency care of individuals with bleeding disorders, such as central nervous system bleeding in patients with hemophilia, emergency management of compartment syndrome, incidence and types of inhibitors in hemophilia and how the inhibitor titer assists in decision making in the care of persons with hemophilia, replacement therapy for FVIII deficiency and calculation of dose for an acute bleed, and the role of hemophilia treatment centers in reducing morbidity and mortality in hemophilia.

The learner will be presented with Reading Room material that may be printed or saved for future reference. A case study is presented with patient chart information and interactive question-and-answer slides to allow the learner the opportunity to apply what has been learned.

The purpose of this learning activity is to enable the learner to explore issues relating to of emergency care of individuals with bleeding disorders, such as central nervous system bleeding in patients with hemophilia, emergency management of compartment syndrome, incidence/types of inhibitors in hemophilia and how the inhibitor titer assists in decision making in the care of persons with hemophilia, replacement therapy for FVIII deficiency and calculation of dose for an acute bleed, and the role of hemophilia treatment centers in reducing morbidity and mortality in hemophilia.

• Relate the clinical considerations for emergency care of patients with hemophilia and von Willebrand disease
• Assess the appropriate approaches for emergency management of bleeding in the central nervous system in patients with hemophilia
• Analyze the appropriate approaches for emergency management of compartment syndrome in patients with hemophilia
• Evaluate the incidence and types of inhibitors in patients with hemophilia
• Explain how the inhibitor titer assists in decision making in the care of patients with hemophilia
• Calculate doses for replacement therapy to manage acute bleeds in patients with hemophilia A
• Relate the effect of hemophilia treatment centers on reduced morbidity and mortality of hemophilia

This learning activity is targeted toward nursing professionals and other members of the multidisciplinary staff at federally funded Hemophilia Treatment Centers (HTCs). The activity also aims to educate physicians and nursing professionals in emergency and primary care, as well as joint/orthopedic health, sports medicine settings, and OB/GYN settings.

• Alice Ma, MD
• Guy Young, MD
• Natalie A. Duncan, MPH (Editor)
• Susan C. Zappa, RN, CPN (Peer reviewer/Editor)

April 1, 2016

5:00 PM Eastern, March 30, 2018

In accordance with the ACCME Standards for Commercial Support of CME, The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (Indiana Hemophilia and Thrombosis Center (IHTC)) have implemented mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a person with a financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) have identified and resolved any and all conflicts of interest prior to the release of this activity.

The speakers and planning committee members listed below have stated they have no significant or substantial relationship with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity:

• Catherine Bevil, EdD, RN
• Lois Colburn
• Natalie A. Duncan, MPH
• Diane Frost, MA, CPP
• Heidi Keeler, PhD, RN

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information the planned and/or present is done so fairly and without bias:

• Anu Hosangadi, MS states that she owns stock in Merck, Bristol Myers Squibb, and Johnson & Johnson.
• Alice Ma, MD states that she receives industry funded research/investigator from Biogen Idec and Baxalta. Dr. Ma is on the Advisory Committee/Boards for Biogen Idec, Baxalta, Kedrion, Novo Nordisk, and Bayer. Dr. Ma is a consultant for Novo Nordisk.
• Jennifer Maahs, MSN, PNP states the she is on the Advisory Board for Baxalta, Biogen, and Novo Nordisk. Ms. Maahs is on the Speakers Bureau for Baxalta and Biogen.
• Amy D. Shapiro, MD states that she is on the Global Steering Committee for Baxalta. Dr. Shapiro is a consultant for Baxalta, Novo Nordisk, Biogen Idec, ProMetic Life Sciences, and Kedrion Biopharma. She is on the Advisory Board for Baxalta, Novo Nordisk, and Biogen IDEC. Dr. Shapiro is on the Data Safety Monitoring Board for Baxalta and is a member of the Novo Nordisk Hemophilia Foundation, and the International Network on Pediatric Hemophilia for Bayer Healthcare Pharmaceuticals. Dr. Shapiro has clinical research protocols with the following: Bayer Healthcare, Biogen Idec, Kedrion Biopharma, Octopharma, PTC Therapeutics, Baxalta, CSL Behring, Novartis Pharmaceuticals, and ProMetic Life Sciences. Dr. Shapiro is Medical Director for the American Thrombosis and Hemostasis Network (ATHN) National Hemophilia Program Coordinating Center and a member of the Medical and Scientific Advisory Council for the National Hemophilia Foundation. Dr. Shapiro notes that she does not accept honoraria personally, and all honoraria or income (grant research funding and consultant fees) generated from the activities above are paid to the Indiana Hemophilia & Thrombosis Center. She has no financial interest in any of the companies.
• Susan C. Zappa, RN, CPN states that she is a consultant and on the Speakers Bureaus for Pfizer, Bayer, and Baxalta. Ms. Zappa is a consultant for Emergent, Novo Nordisk, Grifols, and Octopharma.

The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) requires CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 45 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Review the activity objectives and CME/CE information.
• Review the case and answer the interactive questions.
• Review the Reading Room material, the patient charts, and laboratory data.
• Complete the evaluation, including the attestation of hours attended.
• Complete the post-test with a score of 80% or better.
• Nurses and "other" disciplines: upon successful completion of the post-test your certificate of completion will be available to save or print.
• MDs and PAs: your certificate of completion will be emailed to you by the Center for Continuing Education. For questions, please call Brenda Ram at 402-559-9250 or email bram@unmc.edu.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and Indiana Hemophilia & Thrombosis Center, Inc. (Partners in Bleeding Disorders Education).

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

This activity is provided for 0.75 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

This program is not supported by any commercial or financial interest.

Partners in Bleeding Disorders Education would like to acknowledge the following original contributors of previous versions of the Bleeding Disorders Interactive Primer (Hemophilia Primer) project:

• Alice Ma, MD
• Andra James, MD, MPH
• Bruce Ewenstein, MD, PhD
• Christine Kempton, MD, MSc
• Deborah Brown, MD
• Georges Rivard, MD
• Guy Young, MD
• Jorge Di Paola, MD
• Margaret Ragni, MD, MPH
• Marilyn Manco-Johnson, MD
• Peter Kouides, MD
• Stephanie Seremetis, MD
• Suchitra Acharya, MD
• Sweta Gupta, MBBS, MD, MS
• Thomas Abshire, MD
• Victor Blanchette, MD, FRCP
• W. Keith Hoots, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CE096 - Tattoos, Piercings, and Gauges...Oh My!

The purpose of this activity is to enable the learner to incorporate knowledge about the effects of modifications on the body, such as tattoos, piercings, and gauges, into strategies to communicate risks and increase safe outcomes to persons with bleeding disorders and their families.

• Discuss the use of common body art modifications (tattoos, piercing, and gauges) in individuals with bleeding disorders
• Evaluate each procedure and its associated risks in persons with bleeding disorders
• Review discussion points for healthcare providers and parents of teenagers with bleeding disorders who are considering body art modifications

Nurses involved in the care of bleeding disorder patients who may opt for body art procedures.
Other healthcare professional who, with the increasing prevalence of these procedures, must also be informed about the special considerations of body art in persons with bleeding disorders.

This learning activity explores the increasing popularity of body modifications, including tattoos, piercings, and gauges, in the U.S. population, including among individuals with bleeding disorders. It examines the procedures and potential bleeding risks involved with each form of body modification, and considers whether clotting factor replacement and a treatment plan should be in place prior to each procedure. Finally, this module considers the best approach for both providers and parents toward adolescents and teens who wish to express themselves through body modification.

• Jennifer Maahs, RN-BC, MSN, PNP

October 3, 2016

5:00 PM Eastern, October 4, 2017

The estimated time to complete this activity is 30 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Read the Program Announcement Form
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

This activity is provided for 0.5 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

The Role of the Nurse in Hemophilia Care

The purpose of this module is to familiarize the learner with the critical role nurses play worldwide in the multidisciplinary care team.

• Examine the critical and variable role of the nurse in the care of people with hemophilia.
• Review the role responsibilities of the nurse related to education, care delivery, coordination of the healthcare team, and support of patient and family to learn to live with hemophilia.

While there are some responsibilities that are universal for all nurses, there is also a great deal of variation in the role and responsibilities of nurses in hemophilia care. This learning module describes those roles and responsibilities and some of the variation that may occur throughout the world.

• World Federation of Hemophilia

June 18, 2013

This module was created to describe the worldwide variation in the role and responsibilities of nurses in hemophilia care.

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

17CE037 - Is That OK? Ethical Dilemmas in our Community

The National Hemophilia Foundation (NHF) Ethics Working Group (EWG) & Ethics Committee Alumni are conducting a survey to determine if there is a need for the creation of a regional or local ethics committee to assist members of the HTC community with ethical dilemmas. All members of the HTC community are invited to complete the anonymous survey by clicking here: https://www.surveymonkey.com/r/NHF_EWG.

The purpose of this activity is to enable the learner to build a solid knowledge base on the history, theories, disciplines, and concepts related to ethics in order to accurately identify and address ethical dilemmas that arise in patient care.

• Define ethics
• Discuss the historical context of ethics
• Differentiate ethical theories
• List three ethical disciplines
• Interpret key ethical concepts
• Apply key ethical concepts to dilemmas within the bleeding disorders community

Members of the hemophilia multidisciplinary care team including physicians, nurses, physical therapists, and social workers. Members of the Bleeding Disorders Community interested in learning more about ethics.

This online learning activity provides healthcare professionals and others an opportunity to gain knowledge about ethical theories, key ethical concepts, and the opportunity to apply these theories and concepts through case study examples.

• Sabrina Farina, LMSW
• Kristie Ostash, MD
• James E. Munn, RN-BC, BS, BSN, MS

January 18, 2017

5:00 PM Eastern, January 18, 2018

In accordance with the ACCME Standards for Commercial Support of CME, The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (Indiana Hemophilia and Thrombosis Center (IHTC)) have implemented mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a person with a financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) have identified and resolved any and all conflicts of interest prior to the release of this activity.

The speakers and planning committee members listed below have stated they have no significant or substantial relationship with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity:

• Lois Colburn
• Heidi Keeler, PhD, RN
• Sabrina Farina, LMSW
• Kristie Ostash, MD

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information they planned and/or present is done so fairly and without bias:

Natalie Duncan, MPH states that she received honorarium for CSL Behring for presenting at Coagulation Advisory Board.

James Munn, RN-BC, BS, BSN, MS states that he is a consultant for Bayer. He also states that he is on the advisory board for Aptevo, Biogen, CSL Behring, Genetech, Novo Nordisk, and Shire

The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) requires CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 45 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Review the activity objectives and CME/CE information.
• Review the case and answer the interactive questions.
• Review the Reading Room material, the patient charts, and laboratory data.
• Complete the evaluation, including the attestation of hours attended.
• Complete the post-test with a score of 70% or better.
• Nurses and "other" disciplines: upon successful completion of the post-test your certificate of completion will be available to save or print.
• MDs and PAs: your certificate of completion will be emailed to you by the Center for Continuing Education. For questions, please call Brenda Ram at 402-559-9250 or email bram@unmc.edu.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and Indiana Hemophilia & Thrombosis Center, Inc. (Partners in Bleeding Disorders Education).

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

This activity is provided for 0.75 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This program is not supported by any commercial or financial interest.

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CC042 - Bleeding Disorders Interactive Primer: Sports Injuries in Moderate and Severe Hemophilia

Sports Injuries in Moderate and Severe Hemophilia is an interactive learning activity that describes the diagnostics and treatments of sports-related injuries and complications for patients with moderate and severe hemophilia. The learner will be presented with Reading Room material that may be printed or saved for future reference. Two case studies are presented with patient chart information and interactive question-and-answer slides to allow the learner the opportunity to apply what has been learned.

The purpose of this module is to enable the learner to relate to the diagnostics and treatments of sports-related injuries and complications for patients with moderate and severe hemophilia.

• Explain the pathophysiology of target joint formation.
• Assess the strategies to treat and prevent target joint formation.
• Evaluate the role of physical therapy in hemophilia care.
• Discuss sports issues in hemophilia.
• Examine the challenges of oral emergencies in hemophilia.
• Investigate the use of antifibrinolytic agents and adjunctive therapies in hemophilia.
• Describe the burden of chronic hepatitis C infection in persons with bleeding disorders.

This learning activity is targeted toward nursing professionals and other members of the multidisciplinary staff at federally funded Hemophilia Treatment Centers (HTCs). The activity also aims to educate physicians and nursing professionals in emergency and primary care, as well as joint/orthopedic health and sports medicine settings.

• Margaret V. Ragni, MD, MPH
• Natalie A. Duncan, MPH (Editor)
• Susan C. Zappa, RN, CPN (Peer reviewer/Editor)

April 1, 2016

5:00 PM Eastern, March 30, 2018

In accordance with the ACCME Standards for Commercial Support of CME, The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (Indiana Hemophilia and Thrombosis Center (IHTC)) have implemented mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a person with a financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) have identified and resolved any and all conflicts of interest prior to the release of this activity.

The speakers and planning committee members listed below have stated they have no significant or substantial relationship with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity:

• Catherine Bevil, EdD, RN
• Lois Colburn
• Natalie A. Duncan, MPH
• Diane Frost, MA, CPP
• Heidi Keeler, PhD, RN

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information the planned and/or present is done so fairly and without bias:

• Anu Hosangadi, MS states that she owns stock in Merck, Bristol Myers Squibb, and Johnson & Johnson.
• Jennifer Maahs, MSN, PNP states the she is on the Advisory Board for Baxalta, Biogen, and Novo Nordisk. Ms. Maahs is on the Speakers Bureau for Baxalta and Biogen.
• Margaret Ragni, MD, MPH states that she is on the Advisory Committee/Board for Alnylam and Medscape/Web MD/Biogen. Dr. Ragni has been a chair, speaker at symposium for Baxalta. Dr. Ragni has received research funding from Alnylam, Baxter, Bayer, and SPARK. She has conducted research studies for BSL Behring, Dimension, and Genentech Roches. Dr. Ragni is a consultant for Biomarin, Shire, and Tacere Benitec. She has prepared education materials and speaks for Medscape/WebMD/Biogen and is a DSMB member for Tacere Benitec.
• Amy D. Shapiro, MD states that she is on the Global Steering Committee for Baxalta. Dr. Shapiro is a consultant for Baxalta, Novo Nordisk, Biogen Idec, ProMetic Life Sciences, and Kedrion Biopharma. She is on the Advisory Board for Baxalta, Novo Nordisk, and Biogen IDEC. Dr. Shapiro is on the Data Safety Monitoring Board for Baxalta and is a member of the Novo Nordisk Hemophilia Foundation, and the International Network on Pediatric Hemophilia for Bayer Healthcare Pharmaceuticals. Dr. Shapiro has clinical research protocols with the following: Bayer Healthcare, Biogen Idec, Kedrion Biopharma, Octopharma, PTC Therapeutics, Baxalta, CSL Behring, Novartis Pharmaceuticals, and ProMetic Life Sciences. Dr. Shapiro is Medical Director for the American Thrombosis and Hemostasis Network (ATHN) National Hemophilia Program Coordinating Center and a member of the Medical and Scientific Advisory Council for the National Hemophilia Foundation. Dr. Shapiro notes that she does not accept honoraria personally, and all honoraria or income (grant research funding and consultant fees) generated from the activities above are paid to the Indiana Hemophilia & Thrombosis Center. She has no financial interest in any of the companies.
• Susan C. Zappa, RN, CPN states that she is a consultant and on the Speakers Bureaus for Pfizer, Bayer, and Baxalta. Ms. Zappa is a consultant for Emergent, Novo Nordisk, Grifols, and Octopharma.

The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) requires CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 45 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Review the activity objectives and CME/CE information.
• Review the case and answer the interactive questions.
• Review the Reading Room material, the patient charts, and laboratory data.
• Complete the evaluation, including the attestation of hours attended.
• Complete the post-test with a score of 80% or better.
• Nurses and "other" disciplines: upon successful completion of the post-test your certificate of completion will be available to save or print.
• MDs and PAs: your certificate of completion will be emailed to you by the Center for Continuing Education. For questions, please call Brenda Ram at 402-559-9250 or email bram@unmc.edu.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and Indiana Hemophilia & Thrombosis Center, Inc. (Partners in Bleeding Disorders Education).

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

This activity is provided for 0.75 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

This program is not supported by any commercial or financial interest.

Partners in Bleeding Disorders Education would like to acknowledge the following original contributors of previous versions of the Bleeding Disorders Interactive Primer (Hemophilia Primer) project:

• Alice Ma, MD
• Andra James, MD, MPH
• Bruce Ewenstein, MD, PhD
• Christine Kempton, MD, MSc
• Deborah Brown, MD
• Georges Rivard, MD
• Guy Young, MD
• Jorge Di Paola, MD
• Margaret Ragni, MD, MPH
• Marilyn Manco-Johnson, MD
• Peter Kouides, MD
• Stephanie Seremetis, MD
• Suchitra Acharya, MD
• Sweta Gupta, MBBS, MD, MS
• Thomas Abshire, MD
• Victor Blanchette, MD, FRCP
• W. Keith Hoots, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CC046 – Bleeding Disorders Interactive Primer: Cardiovascular Disease in an Adult with Hemophilia

Cardiovascular Disease in an Adult with Hemophilia is an interactive learning activity that reviews the prevalence and management of cardiovascular disease in adults with hemophilia. The module reviews the important considerations in this population that are emerging as persons with hemophilia begin to achieve normal lifespans.

The learner will be presented with Reading Room material that may be printed or saved for future reference. A case study is presented with patient chart information and interactive question-and-answer slides to allow the learner the opportunity to apply what has been learned.

The purpose of this module is to review the prevalence and management of cardiovascular disease in adults with hemophilia and the important considerations in this population that are emerging as persons with hemophilia begin to achieve normal lifespans.

• Review the prevalence of cardiovascular disease among adults with hemophilia
• Recommend routine screenings and evaluations for individuals with hemophilia
• Explain the appropriate use of antithrombotic agents in individuals with hemophilia
• Evaluate the use of desmopressin acetate in individuals with hemophilia who have cardiovascular disease
• Describe the hemostatic considerations in individuals with hemophilia who require invasive cardiovascular procedures
• Identify the potential major complications associated with cardiovascular procedures and their management in individuals with hemophilia

This learning activity is intended for physicians and nursing professionals at federally funded hemophilia treatment centers (HTCs) and health care providers in other health care settings, such as emergency and primary care, and obstetrics and gynecology.

• Anne Greist, MD
• Natalie A. Duncan, MPH (Editor)
• Susan C. Zappa, RN, CPN (Peer reviewer/Editor)

April 1, 2016

5:00 PM Eastern, March 30, 2018

In accordance with the ACCME Standards for Commercial Support of CME, The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (Indiana Hemophilia and Thrombosis Center (IHTC)) have implemented mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a person with a financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) have identified and resolved any and all conflicts of interest prior to the release of this activity.

The speakers and planning committee members listed below have stated they have no significant or substantial relationship with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity:

• Catherine Bevil, EdD, RN
• Lois Colburn
• Natalie A. Duncan, MPH
• Diane Frost, MA, CPP
• Heidi Keeler, PhD, RN

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information the planned and/or present is done so fairly and without bias:

• Anu Hosangadi, MS states that she owns stock in Merck, Bristol Myers Squibb, and Johnson & Johnson.
• Jennifer Maahs, MSN, PNP states the she is on the Advisory Board for Baxalta, Biogen, and Novo Nordisk. Ms. Maahs is on the Speakers Bureau for Baxalta and Biogen.
• Anne Greist, MD states that she and her spouse/partner own shares in Epic.
• Amy D. Shapiro, MD states that she is on the Global Steering Committee for Baxalta. Dr. Shapiro is a consultant for Baxalta, Novo Nordisk, Biogen Idec, ProMetic Life Sciences, and Kedrion Biopharma. She is on the Advisory Board for Baxalta, Novo Nordisk, and Biogen IDEC. Dr. Shapiro is on the Data Safety Monitoring Board for Baxalta and is a member of the Novo Nordisk Hemophilia Foundation, and the International Network on Pediatric Hemophilia for Bayer Healthcare Pharmaceuticals. Dr. Shapiro has clinical research protocols with the following: Bayer Healthcare, Biogen Idec, Kedrion Biopharma, Octopharma, PTC Therapeutics, Baxalta, CSL Behring, Novartis Pharmaceuticals, and ProMetic Life Sciences. Dr. Shapiro is Medical Director for the American Thrombosis and Hemostasis Network (ATHN) National Hemophilia Program Coordinating Center and a member of the Medical and Scientific Advisory Council for the National Hemophilia Foundation. Dr. Shapiro notes that she does not accept honoraria personally, and all honoraria or income (grant research funding and consultant fees) generated from the activities above are paid to the Indiana Hemophilia & Thrombosis Center. She has no financial interest in any of the companies.
• Susan C. Zappa, RN, CPN states that she is a consultant and on the Speakers Bureaus for Pfizer, Bayer, and Baxalta. Ms. Zappa is a consultant for Emergent, Novo Nordisk, Grifols, and Octopharma.

The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) requires CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 45 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Review the activity objectives and CME/CE information.
• Review the case and answer the interactive questions.
• Review the Reading Room material, the patient charts, and laboratory data.
• Complete the evaluation, including the attestation of hours attended.
• Complete the post-test with a score of 75% or better.
• Nurses and "other" disciplines: upon successful completion of the post-test your certificate of completion will be available to save or print.
• MDs and PAs: your certificate of completion will be emailed to you by the Center for Continuing Education. For questions, please call Brenda Ram at 402-559-9250 or email bram@unmc.edu.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and Indiana Hemophilia & Thrombosis Center, Inc. (Partners in Bleeding Disorders Education).

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

This activity is provided for 0.75 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

This program is not supported by any commercial or financial interest.

Partners in Bleeding Disorders Education would like to acknowledge the following original contributors of previous versions of the Bleeding Disorders Interactive Primer (Hemophilia Primer) project:

• Alice Ma, MD
• Andra James, MD, MPH
• Bruce Ewenstein, MD, PhD
• Christine Kempton, MD, MSc
• Deborah Brown, MD
• Georges Rivard, MD
• Guy Young, MD
• Jorge Di Paola, MD
• Margaret Ragni, MD, MPH
• Marilyn Manco-Johnson, MD
• Peter Kouides, MD
• Stephanie Seremetis, MD
• Suchitra Acharya, MD
• Sweta Gupta, MBBS, MD, MS
• Thomas Abshire, MD
• Victor Blanchette, MD, FRCP
• W. Keith Hoots, MD
• Ashwin Vasudevamurthy, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

17CE058 - Dental Management for Persons with Bleeding Disorders

The purpose of this activity is to enable the learner to develop knowledge related to the role of dental care in the bleeding disorders comprehensive care model and to apply that knowledge to recommendations for preventive care, treatment of dental conditions, and hemostatic management prior to and following dental procedures.

• Explain how dental care fits with the model of comprehensive care in persons with bleeding disorders
• Discuss the importance of dental care in persons with bleeding disorders, including how proper preventive care contributes to overall health
• Examine the importance of coordination of care between the patient, dental provider, and hemophilia treatment center
• Assess bleeding risk associated with dental procedures
• Describe hemostatic management prior to and following dental procedures
• Distinguish whether a specific dental condition is a medical emergency in a person with a bleeding disorder

Dental hygienists, dentists, nurses, and other health care professionals who are part of a U.S. hemophilia treatment center (HTC) comprehensive care team and seek information on dental management in persons with bleeding disorders.

This interactive learning module provides information about the dental considerations in management of individuals with hemophilia and other bleeding disorders, including an overview of preventive oral care in persons with bleeding disorders, low versus high risk bleeding events, hemostatic management prior to and following dental procedures, and common dental emergencies. Case studies and question-and-answer slides are included in order to allow the learner the opportunity to apply the knowledge gained.

• Janet Mulherin, RDH
• Jim Munn, RN-BC, BS, BSN, MS
• Rea Rhoads, LDH
• Karen Ridley, MSDH, BS, RDH

June 14, 2017

5:00 PM Eastern, June 14, 2018

The estimated time to complete this activity is 60 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Read the Program Announcement Form
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

This activity is provided for 1.0 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

The University of Nebraska Medical Center College of Dentistry Office of Continuing Education is an ADA CERP Recognized Provider.

ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to ADA CERP at www.ada.org/cerp

ADA CERP credit is valid form October 4, 2016 to October 4, 2017.

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

17CE057 - A School Nurse's Guide to Bleeding Disorders: Hemophilia

The purpose of this activity is to enable the learner to obtain knowledge about hemophilia, its treatment, and any accommodations that must be made in order to provide education to the student with hemophilia.

• Recall basic information about the symptoms, severity, and inheritance of hemophilia;
• Identify common locations and symptoms for joint and muscle bleeding in hemophilia;
• Recognize the importance of early treatment of bleeding episodes;
• Differentiate between episodic and prophylactic treatment of hemophilia; and
• Integrate strategies in the school setting to promote a safe and positive learning environment.

This learning activity is targeted toward nurses in schools attended by a child with hemophilia. It may also be helpful for teachers, physical education teachers, school administrators and guidance counselors as well as other educators and healthcare professionals needing an introduction to school-related considerations in hemophilia.

A School Nurse's Guide to Bleeding Disorders: Hemophilia covers nursing considerations that must be made in schools attended by a student with hemophilia. The activity includes basic information about the symptoms, severity, and inheritance of hemophilia; common locations and symptoms of joint and muscle bleeding; treatment of hemophilia, including treatment of bleeding episodes and prophylactic treatment; and strategies that a school might integrate to promote a safe and positive learning environment for the student with hemophilia.

• Lisa Bowman, RN, ASN
• Laura Cole, RN

May 12, 2017

5:00 PM, Eastern, May 12, 2018

The estimated time to complete this activity is 30 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Read the Program Announcement Form
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

This activity is provided for 0.50 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

• Overview - Margaret V. Ragni, MD, MPH
• Case 1: Do Bleeding Scores Improve VWD Diagnosis in Children? - Paula James, MD, FRCPC
• Case 2: Why Does Bleeding Persist in the VWD Patient After Emergency Department Visits? - Margaret V. Ragni, MD, MPH
• Case 3: Why Do Women with VWD Develop PPH Despite Treatment? - Alice D. Ma, MD
• Discussion/Q&A - Faculty

• Evaluate the uses and limitations of bleeding assessment tools in pediatric patients with von Willebrand disease (VWD)
• Describe postpartum levels of von Willebrand factor and their impact on quality of life in women with VWD
• Review the management options for VWD and their limitations
• Describe how evolving therapies may impact standard practice for management of patients with VWD

This activity has been designed to meet the educational needs of physicians and other health professionals, including nurse practitioners and physician assistants, who treat pediatric and adult patients with VWD. Given that menorrhagia and postpartum bleeding represent major unmet health needs in women with VWD, the activity is also relevant to obstetricians and gynecologists who are involved in providing care for patients with VWD.

• Paula D. James, MD, FRCPC
  Professor, Department of Medicine
  Division of Hematology
  Pathology and Molecular Medicine
  Queen's University
  Ontario, Canada
  
  Dr. James discloses that she is on the Advisory Board for scientific information of Biogen. She also discloses receiving Grant/Research Support from CSL Behring, Bayer HealthCare Pharmaceuticals, and Octapharma.
  
  
• Alice D. Ma, MD
  Professor of Medicine
  University of North Carolina
  Hemophilia and Thrombosis Center
  Chapel Hill, NC
  
  Dr. Ma discloses she is on the Advisory Board for scientific information for Novo Nordisk and Baxalta (now Shire). She is a consultant for marketing purposes for Novo Nordisk. Dr. Ma has received Grant/Research support for University of North Carolina from Baxalta (now Shire).
  
  
• Margaret V. Ragni, MD, MPH (Moderator/Chair)
  Professor of Medicine, Division, Hematology/Oncology
  Director, Hemophilia Center of Western PA
  Pittsburgh, PA
  
  Dr. Ragni discloses that she is on Advisory Boards for scientific information and a Consultant for clinical trial design for Alnylam, Baxalta (now Shire), Biomarin, Baxter, Genentech/Roche, Tacere Therapeutics (a wholly-owned subsidiary of Benitec Biopharma), and Johns Hopkins CME. Dr. Ragni is a Board Member of the ASH Scientific Committee and on the Advisory Board of Foundation for Women and Girls with Blood Disorders. She states she has received Grant/Research Support from Alnylam, Baxter, Biogen, Chiron, CSL Behring, Dimensions, Genentech/Roche, University of Southern California (HUGS), Novo Nordisk, OPKO, SPARK, and Vascular Medicine Institute.

February 2, 2017

February 2, 2018

Planning Committee w/ Disclosures

• Laurie Ermentrout states that she has no relevant financial relationships to disclose.
• John "JD" Juchniewicz, MCIS, CHCP, states that he has no relevant financial relationships to disclose.
• Anu Hosangadi, MS, states that both she and her spouse own stock in Biogen, Bristol-Myers Squibb, Celgene Corporation, Gilead Sciences, Inc., Johnson and Johnson, Merck and Co. Inc., Novo Nordisk Inc.
• Lisa Kehs states that she has no relevant financial relationships to disclose.

Off-Label Disclosure

The activity may contain discussion of off-label or investigational information.

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre- and post-tests (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.

This activity is supported by an educational grant from Shire.

The content for this activity is based on a satellite symposium preceding the 58th ASH Annual Meeting and Exposition on December 2, 2016.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Academy of CME, Inc., (Academy) and E&ampS MedEd Group, Inc. American Academy of CME, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

American Academy of CME, Inc., designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or E&S MedEd Group, Inc. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

For questions about CME credit or the activity, please contact: CEServices@academycme.org

For technical questions about the website, please contact: educationlab@healio.com

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm.

© 2017. This CME-certified activity is held as copyrighted © by American Academy of CME and E&S MedEd Group. Through this notice, the Academy and E&S grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CC044 - Bleeding Disorders Interactive Primer: Treatment of Bleeding Disorders: Special Considerations (Module 2)

Treatment of Bleeding Disorders: Special Considerations (Module 2) is an interactive learning activity that provides the learner the opportunity to learn about special challenges in bleeding disorders care, including carrier status, bleeding history, treatment products for carriers and the mildly affected or infrequently exposed, the incidence and types of inhibitors, and the occurrence of compartment syndrome.

The learner will be presented with Reading Room material that may be printed or saved for future reference. A case study is presented with patient chart information and interactive question-and-answer slides to allow the learner the opportunity to apply what has been learned.

The purpose of this learning activity is to enable the learner to learn about special challenges in bleeding disorders care, including carrier status, bleeding history, treatment products for carriers and the mildly affected or infrequently exposed, the incidence and types of inhibitors, and the occurrence of compartment syndrome.

• Describe the accurate determination of carrier status
• Explain the importance of obtaining a bleeding history
• Assess the use of desmopressin in carriers and patients with mild factor VIII deficiency
• Evaluate the use of infusion therapy, including continuous infusion, for surgical procedures
• Describe appropriate infusion products in infrequently treated or previously unexposed patients
• Summarize the incidence and types of inhibitors in congenital hemophilia
• Describe the use of the inhibitor titer to determine hemostatic treatment options
• Identify the signs and symptoms of a compartment syndrome and its sequelae

This learning activity is targeted toward nursing professionals and other members of the multidisciplinary staff at federally funded Hemophilia Treatment Centers (HTCs). The activity also aims to educate physicians and nursing professionals in emergency and primary care, as well as joint/orthopedic health, sports medicine settings, and OB/GYN settings.

• Guy Young, MD
• Natalie A. Duncan, MPH (Editor)
• Susan C. Zappa, RN, CPN (Peer reviewer/Editor)

April 1, 2016

5:00 PM Eastern, March 30, 2018

In accordance with the ACCME Standards for Commercial Support of CME, The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (Indiana Hemophilia and Thrombosis Center (IHTC)) have implemented mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a person with a financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) have identified and resolved any and all conflicts of interest prior to the release of this activity.

The speakers and planning committee members listed below have stated they have no significant or substantial relationship with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity:

• Catherine Bevil, EdD, RN
• Lois Colburn
• Natalie A. Duncan, MPH
• Diane Frost, MA, CPP
• Heidi Keeler, PhD, RN

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information the planned and/or present is done so fairly and without bias:

<
• Anu Hosangadi, MS states that she owns stock in Merck, Bristol Myers Squibb, and Johnson & Johnson.
• Jennifer Maahs, MSN, PNP states the she is on the Advisory Board for Baxalta, Biogen, and Novo Nordisk. Ms. Maahs is on the Speakers Bureau for Baxalta and Biogen.
• Amy D. Shapiro, MD states that she is on the Global Steering Committee for Baxalta. Dr. Shapiro is a consultant for Baxalta, Novo Nordisk, Biogen Idec, ProMetic Life Sciences, and Kedrion Biopharma. She is on the Advisory Board for Baxalta, Novo Nordisk, and Biogen IDEC. Dr. Shapiro is on the Data Safety Monitoring Board for Baxalta and is a member of the Novo Nordisk Hemophilia Foundation, and the International Network on Pediatric Hemophilia for Bayer Healthcare Pharmaceuticals. Dr. Shapiro has clinical research protocols with the following: Bayer Healthcare, Biogen Idec, Kedrion Biopharma, Octopharma, PTC Therapeutics, Baxalta, CSL Behring, Novartis Pharmaceuticals, and ProMetic Life Sciences. Dr. Shapiro is Medical Director for the American Thrombosis and Hemostasis Network (ATHN) National Hemophilia Program Coordinating Center and a member of the Medical and Scientific Advisory Council for the National Hemophilia Foundation. Dr. Shapiro notes that she does not accept honoraria personally, and all honoraria or income (grant research funding and consultant fees) generated from the activities above are paid to the Indiana Hemophilia & Thrombosis Center. She has no financial interest in any of the companies.
• Susan C. Zappa, RN, CPN states that she is a consultant and on the Speakers Bureaus for Pfizer, Bayer, and Baxalta. Ms. Zappa is a consultant for Emergent, Novo Nordisk, Grifols, and Octopharma.

The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) requires CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 45 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Review the activity objectives and CME/CE information.
• Review the case and answer the interactive questions.
• Review the Reading Room material, the patient charts, and laboratory data.
• Complete the evaluation, including the attestation of hours attended.
• Complete the post-test with a score of 80% or better.
• Nurses and "other" disciplines: upon successful completion of the post-test your certificate of completion will be available to save or print.
• MDs and PAs: your certificate of completion will be emailed to you by the Center for Continuing Education. For questions, please call Brenda Ram at 402-559-9250 or email bram@unmc.edu.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and Indiana Hemophilia & Thrombosis Center, Inc. (Partners in Bleeding Disorders Education).

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

This activity is provided for 0.75 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

This program is not supported by any commercial or financial interest.

Partners in Bleeding Disorders Education would like to acknowledge the following original contributors of previous versions of the Bleeding Disorders Interactive Primer (Hemophilia Primer) project:

• Alice Ma, MD
• Andra James, MD, MPH
• Bruce Ewenstein, MD, PhD
• Christine Kempton, MD, MSc
• Deborah Brown, MD
• Georges Rivard, MD
• Guy Young, MD
• Jorge Di Paola, MD
• Margaret Ragni, MD, MPH
• Marilyn Manco-Johnson, MD
• Peter Kouides, MD
• Stephanie Seremetis, MD
• Suchitra Acharya, MD
• Sweta Gupta, MBBS, MD, MS
• Thomas Abshire, MD
• Victor Blanchette, MD, FRCP
• W. Keith Hoots, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CC043 - Bleeding Disorders Interactive Primer: Treatment of Bleeding Disorders: Special Considerations (Module 1)

Treatment of Bleeding Disorders: Special Considerations (Module 1) is an interactive learning activity that presents the various treatments and therapies available for bleeding disorders, possible contraindications for the use of NSAIDs in persons with bleeding disorders, various screening tests used to diagnose bleeding disorders, and emergency care required for individuals with bleeding disorders.

The learner will be presented with Reading Room material that may be printed or saved for future reference. A case study is presented with patient chart information and interactive question-and-answer slides to allow the learner the opportunity to apply what has been learned.

The purpose of this activity is to enable the learner to evaluate various treatments and therapies available for bleeding disorders, possible contraindications for the use of NSAIDs in persons with bleeding disorders, various screening tests used to diagnose bleeding disorders, and emergency care required for individuals with bleeding disorders.

• Explain replacement therapy for hemophilia B and calculate appropriate doses
• Discuss emergency care of individuals with hemophilia
• Relate the urgency of acute gastrointestinal hemorrhage in hemophilia B
• Examine the use of nonsteroidal anti-inflammatory drugs in persons with bleeding disorders
• Assess the use of antifibrinolytic agents as adjunct therapy
• Evaluate the use of the activated partial thromboplastin time (APTT) in persons with mild FIX deficiency
• Summarize the screening tests used for diagnosis of bleeding disorders
• Describe the impact of hepatitis C infection in persons with bleeding disorders

This learning activity is targeted toward nursing professionals and other members of the multidisciplinary staff at federally funded Hemophilia Treatment Centers (HTCs). The activity also aims to educate physicians and nursing professionals in emergency and primary care, as well as joint/orthopedic health, sports medicine settings, and OB/GYN settings.

• Deborah Brown, MD
• Alice Ma, MD
• Natalie A. Duncan, MPH (Editor)
• Susan C. Zappa, RN, CPN (Peer reviewer/Editor)

April 1, 2016

5:00 PM Eastern, March 30, 2018

In accordance with the ACCME Standards for Commercial Support of CME, The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (Indiana Hemophilia and Thrombosis Center (IHTC)) have implemented mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.

It is the policy of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a person with a financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) have identified and resolved any and all conflicts of interest prior to the release of this activity.

The speakers and planning committee members listed below have stated they have no significant or substantial relationship with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity:

• Catherine Bevil, EdD, RN
• Lois Colburn
• Natalie A. Duncan, MPH
• Diane Frost, MA, CPP
• Heidi Keeler, PhD, RN

The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information the planned and/or present is done so fairly and without bias:

• Deborah Brown, MD states that she receives industry funded research/investigator from Baxalta.
• Anu Hosangadi, MS states that she owns stock in Merck, Bristol Myers Squibb, and Johnson & Johnson.
• Alice Ma, MD states that she receives industry funded research/investigator from Biogen Idec and Baxalta. Dr. Ma is on the Advisory Committee/Boards for Biogen Idec, Baxalta, Kedrion, Novo Nordisk, and Bayer. Dr. Ma is a consultant for Novo Nordisk.
• Jennifer Maahs, MSN, PNP states the she is on the Advisory Board for Baxalta, Biogen, and Novo Nordisk. Ms. Maahs is on the Speakers Bureau for Baxalta and Biogen.
• Amy D. Shapiro, MD states that she is on the Global Steering Committee for Baxalta. Dr. Shapiro is a consultant for Baxalta, Novo Nordisk, Biogen Idec, ProMetic Life Sciences, and Kedrion Biopharma. She is on the Advisory Board for Baxalta, Novo Nordisk, and Biogen IDEC. Dr. Shapiro is on the Data Safety Monitoring Board for Baxalta and is a member of the Novo Nordisk Hemophilia Foundation, and the International Network on Pediatric Hemophilia for Bayer Healthcare Pharmaceuticals. Dr. Shapiro has clinical research protocols with the following: Bayer Healthcare, Biogen Idec, Kedrion Biopharma, Octopharma, PTC Therapeutics, Baxalta, CSL Behring, Novartis Pharmaceuticals, and ProMetic Life Sciences. Dr. Shapiro is Medical Director for the American Thrombosis and Hemostasis Network (ATHN) National Hemophilia Program Coordinating Center and a member of the Medical and Scientific Advisory Council for the National Hemophilia Foundation. Dr. Shapiro notes that she does not accept honoraria personally, and all honoraria or income (grant research funding and consultant fees) generated from the activities above are paid to the Indiana Hemophilia & Thrombosis Center. She has no financial interest in any of the companies.
• Susan C. Zappa, RN, CPN states that she is a consultant and on the Speakers Bureaus for Pfizer, Bayer, and Baxalta. Ms. Zappa is a consultant for Emergent, Novo Nordisk, Grifols, and Octopharma.

The University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and the Partners in Bleeding Disorders Education (IHTC) requires CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Accredited status as a provider of continuing nursing education refers only to the University of Nebraska Medical Center College of Nursing Continuing Nursing Education continuing education activities, and does not imply UNMC or American Nurses Credentialing Center’s Commission on Accreditation endorsement of any commercial supporters.

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 45 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Review the activity objectives and CME/CE information.
• Review the case and answer the interactive questions.
• Review the Reading Room material, the patient charts, and laboratory data.
• Complete the evaluation, including the attestation of hours attended.
• Complete the post-test with a score of 80% or better.
• Nurses and "other" disciplines: upon successful completion of the post-test your certificate of completion will be available to save or print.
• MDs and PAs: your certificate of completion will be emailed to you by the Center for Continuing Education. For questions, please call Brenda Ram at 402-559-9250 or email bram@unmc.edu.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center’s Commission on Accreditation (ANCC) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, College of Nursing Continuing Nursing Education and Indiana Hemophilia & Thrombosis Center, Inc. (Partners in Bleeding Disorders Education).

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

This activity is provided for 0.75 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

This program is not supported by any commercial or financial interest.

Partners in Bleeding Disorders Education would like to acknowledge the following original contributors of previous versions of the Bleeding Disorders Interactive Primer (Hemophilia Primer) project:

• Alice Ma, MD
• Andra James, MD, MPH
• Bruce Ewenstein, MD, PhD
• Christine Kempton, MD, MSc
• Deborah Brown, MD
• Georges Rivard, MD
• Guy Young, MD
• Jorge Di Paola, MD
• Margaret Ragni, MD, MPH
• Marilyn Manco-Johnson, MD
• Peter Kouides, MD
• Stephanie Seremetis, MD
• Suchitra Acharya, MD
• Sweta Gupta, MBBS, MD, MS
• Thomas Abshire, MD
• Victor Blanchette, MD, FRCP
• W. Keith Hoots, MD

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

17CE051 - A School Nurse's Guide to Bleeding Disorders: von Willebrand Disease

The purpose of this activity is to enable the learner to obtain knowledge about von Willebrand disease (VWD), its treatment, and any accommodations that must be made in order to provide a safe and positive learning environment to the student with VWD.

• Apply basic information related to the etiology and symptoms of von Willebrand disease (VWD) to clinical practice with students
• Recognize common treatments utilized for VWD within the school setting.
• Integrate strategies in the school setting to promote a safe and positive learning environment.

This learning module is targeted toward professional school nurses in schools attended by a child with von Willebrand Disease (VWD), teachers, physical education instructors, administrators, and guidance counselors, and other educators and healthcare professionals who require an introduction to school-related considerations for students with VWD.

“A School Nurse’s Guide to Bleeding Disorders: von Willebrand Disease” contains information about von Willebrand Disease (VWD), its treatment, and accommodations that must be made in order to promote a safe and positive learning environment for the student with VWD. This includes a definition of VWD and a description of common symptoms; description of VWD treatment; and exploration of the Hemophilia Treatment Center (HTC) comprehensive care team as an essential resource in managing the student with VWD.

• Lisa Bowman, RN, ASN
• Laura Cole, RN

March 27, 2017

5:00 PM, Eastern, March 27, 2018

The estimated time to complete this activity is 30 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Read the Program Announcement Form
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

This activity is provided for 0.5 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.

16CE076 - An Overview of the Background, Inheritance, and Physiology of von Willebrand Disease

The purpose of this learning activity is to enable the learner to develop an enhanced understanding of the nature of von Willebrand disease (VWD) by providing information about the discovery and evolution of knowledge about VWD, the production and functions of von Willebrand factor (VWF), and the differentiation of the classifications of VWD.

• Explain the history of von Willebrand Disease (VWD) including its discovery and evolution
• Examine the production and functions of von Willebrand factor (VWF)
• Differentiate among the multiple classifications for VWD, including type 1, type 2, and type 3

Nurses and other healthcare professionals employed within the federally recognized U.S. hemophilia treatment center network (USHTCN) seeking training on von Willebrand disease (VWD) relating to the history and evolution of our understanding of the condition, the role of von Willebrand factor (VWF), and the differentiation of the multiple classifications of VWD.

An Overview of the Background, Inheritance, and Physiology of von Willebrand Disease will explain how the disease was first discovered and the evolution of knowledge about it. The production of von Willebrand factor will be examined. The different types of VWD will be presented so the learner can distinguish between them.

• Roshni Kulkarni, MD
• Usha M Reddy, MD
• Bruce Evatt, MD
• Connie Miller, PhD

June 19, 2017

5:00 PM Eastern, June 19, 2018

The estimated time to complete this activity is 45 minutes. In order to receive contact hours, you must complete the following prior to the course expiration date:

• Read the Program Announcement Form
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

This activity is provided for 0.75 contact hours under ANCC criteria.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education has been awarded Accreditation with Distinction, the highest recognition awarded by the American Nurses Credentialing Center's Accreditation Program. This distinction is valid through 2020.

If you have any questions about this activity, please contact Natalie Duncan in Indianapolis, IN, 317-871-0011 ext 273, toll-free 877-256-8837, or via email at nduncan@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.